Estrogens and Breast Cancer
Estrogen administration is accepted by most epidemiologists as a risk factor of human endometrial adenocarcinoma (1, 2) . Thus, estrogens unopposed by progestins increase the risk of uterine tumors. This risk increases with increasing doses of estrogen and with the length of treatment (3) . Obesity also increases uterine tumor risk, most likely because the aromatase activity of adipose cells elevates circulating estrone levels (3, 4) .
Increasing evidence shows that elevated levels of estrogens in the body are also a risk factor in breast cancer. Exogenous estrogens, alone or in combination with jliehr@marlin.utmb.edu
Abbreviations used: E2, 17J-estradiol; LHP, lipid hydroperoxides; 2-OH-E2, 2-hydroxyestradiol; 4-OH-E2, 4-hydroxyestradiol. progestin, elevate breast cancer risk (5) (6) (7) . Progestin added to the estrogen medications does not inhibit mammary carcinogenesis (8) because the former hormone appears to be the primary mitogen of mammary ductal epithelial cells (9) , whereas estrogen appears to function in this manner in the uterus. This role of estrogen in human breast carcinogenesis is supported by risk factors of breast cancer such as high serum or urine estrogen levels (10, 11) , the early onset of menstruation, or late menopause (12) . These relationships are illustrated by the fact that the breast cancer risk of a woman undergoing menopause at 45 years of age is half that of a woman experiencing menopause at 55 years of age (5, 6, 12 (13, 14) , pituitary (15, 16) , prostate (17) , uterine cervix (18) , testes (19) , and liver (20) . In addition, the estrogen-induced kidney tumorigenesis in Syrian hamsters has been used extensively for mechanistic studies (21) Several synthetic steroidal estrogens were only weakly carcinogenic in this model system despite their powerful hormonal potencies (21, 24, 25) . This lack of correlation of estrogenic characteristics with carcinogenic activities of steroids led to the conclusion that hormonal potency of an estrogen was necessary but not sufficient for tumor induction (24, 25) . It (26, 27) . However, an elevated formation of 4-hydroxyestrogen metabolites by specific estrogen-4-hydroxylases has been detected in hamster kidney (28) , mouse uterus (29) , and rat pituitary (30)-all organs in which estrogens are known to induce tumors (13) (14) (15) (16) 21 (54) .
metabolic redox cycling between hydroquinone and quinone forms (Figure 1) . The catecholestrogen quinone intermediates may form covalent DNA adducts (31, 32) . Moreover, metabolic redox cycling generates free radicals that are capable of direct or indirect covalent modification of DNA (Figure 2) (33,34) . In line with this hypothesis, hydroxy radical damage such as 8-hydroxyguanine bases of DNA or DNA single strand breaks have been detected in the kidney of hamsters treated with estradiol (35) (36) (37) . In addition, intranuclear, site-specific redox cycling involving catecholestrogen metabolites and copper ions may induce DNA damage by reactive oxygen, which is not mediated by metabolizing enzymes (38) .
Lipid hydroperoxides (LHP) play a central role in the DNA damage process by catechol estrogens (Figure 2 ). LHP are formed by free radicals generated by redox cycling. They, in turn, support redox cycling as cofactors in the cytochrome P4501A-mediated oxidation step of the redox cycle (33, 39) . Finally, LHP may decompose into reactive aldehydes such as malondialdehyde, which covalendy bind to DNA (40) .
One or several of these classes of covalent DNA damage may initiate and/or promote the carcinogenic process ( Figure  3) . Tumors (6) . H202 may be reduced by to hydroxy radicals, which initiate the formation of LHP. DNA may be covalently modified by aldehyde d tion products of LHP, by hydroxy radicals, or by covalent binding of quinone metabolites. Although 2 brackets), the most common metabolite formed by liver enzymes, is capable of undergoing metabolic red its contribution to free radical generation and DNA damage may be negligible because it is convertec gates by phase 11 metabolism enzymes much more efficiently than the 4-hydroxylated isomer. The p estrogen metabolites to damage cells is potentiated by redox cycling and by the initiation of free radical Details of this pathway are outlined in a recent review by Yager and Liehr (54). 6, 37) complexity requires a multidisciplinary 5) design of experiments because emphasizing (39) various aspects of carcinogenesis has not er (52) sufficed to explain the full sequence of events resulting in the appearance of mam-:F-7 breast mary tumors. The mechanisms outlined above are complex and difficult to understand, yet represent the best explanation to MCF-7 date of the experimental data. Additional human research into better animal models, into the nocarci-relation of estrogen metabolism to breast stradiol cancer, and into better assays of estrogen droxyla-metabolites and metabolizing enzymes will !strogens provide a more detailed understanding of enzyme mammary carcinogenesis. '44,45 
